• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Case 5

March 2, 2011

Urine bacterial culture and antimicrobial sensitivity

Organism: Pseudomonas species > 100,000 cfu/ml

Antibiotic (µg/ml)

MIC

Interpretation

Reference range

Amikacin

≤ 8

S

8-64

Amoxicillin/clavulanate

NA

R

4-32

Ampicillin/amoxicillin

NA

Advertisement

R

0.25-32

Cefpodoxime

≥ 8

R

2-8

Cephalexin

NA

R

4-32

Enrofloxacin

2

I

0.5-4

Marbofloxacin

1

S

0.5-4

Nitrofurantoin

> 128

R

16-128

Trimethoprim/sulfonamide

NA

R

0.5-4

Ticarcillin

≤16

S

16-128

NA = not applicable

S = susceptible, R= resistant, I = intermediate

The urine bacterial culture results indicate that Coco has developed a resistant UTI.

Interpretation of MIC data

The minimal inhibitory concentration (MIC) is the lowest amount (dilution) of antibiotic that inhibits bacterial growth. In order to be effective, the antibiotic you choose must reach this MIC at the site of the infection. However, in vitro susceptibility testing may not translate to in vivo efficacy since the MIC data is based on serum antibiotic concentrations and does not account for patient or drug factors. For example, for a UTI, you would want to choose a drug that concentrates well in the urine (e.g. amoxicillin), whereas for treatment of a patient with pneumonia, you would want to consider a drug that concentrates well in WBCs (e.g. fluoroquinolones).

Obviously, you also want to choose a drug that demonstrates a MIC below the susceptible breakpoint (below the lowest end of the reference range provided). Organisms with antibiotic MICs above the high end of the breakpoint range are considered resistant to that antibiotic, and those with MICs within the reference range are typically considered to have intermediate sensitivity to that antibiotic. In some cases, drugs classified as intermediate may still be considered for treating the infection depending on the site of the infection and the drug. For example, a drug that demonstrates intermediate sensitivity may still be an appropriate choice if it can be used topically at the site of the infection, such as in patients with otitis.

QUESTION 3

What is your new treatment plan for Coco at this time?

a) Recommend treatment with amikacin and monitor her renal function parameters closely.

b) Dispense marbofloxacin for three weeks and recommend that Coco return for a recheck urinalysis in one week.

c) Recommend an extended sensitivity panel to identify another antibiotic that may be used at this time.

d) Recommend an abdominal ultrasonographic examination to look for bladder abnormalities that may be predisposing Coco to an infection.

 

<< Back | Next Step >>

Related Content:

Association
American Veterinary Medical Foundation welcomes new executive director
American Veterinary Medical Foundation welcomes new executive director
New certificate program addresses the importance of self-care
New certificate program addresses the importance of self-care
2023 AVMA Animal Welfare Award winner announced
2023 AVMA Animal Welfare Award winner announced

Advertisement

Latest News

Oldest aardvark in Europe passes away

Integrative approach to treating Giardia lamblia infections

Innovative digital microscopy platform is launched

Enhanced pet health and wellness app now available

View More Latest News
Advertisement